Key Takeaways
- Ocugen signs a term sheet for a licensing agreement granting exclusive rights to OCU400 in Korea.
- The agreement includes up to $11 million in upfront fees and development milestones, plus 25% royalties on net sales.
- OCU400 aims to treat retinitis pigmentosa, with a Phase 3 clinical trial underway and a planned Biologics License Application in mid-2026.
Licensing Agreement Details
Ocugen, Inc. has announced a binding term sheet with a leading Korean pharmaceutical company for the exclusive rights to market OCU400, a novel gene therapy aimed at treating retinitis pigmentosa (RP). This agreement is structured to provide financial benefits as Ocugen will receive up to $11 million in upfront fees and near-term development milestone payments.
Under the terms, Ocugen will earn $1 million for every $15 million in net sales generated in Korea, alongside a 25% royalty on net sales from its partner. Additionally, Ocugen will be responsible for the manufacturing and supply of OCU400.
With around 15,000 individuals in South Korea suffering from RP, this partnership represents a significant opportunity to improve treatment options for patients in the region. Dr. Shankar Musunuri, Ocugen’s Chairman, CEO, and Co-founder, emphasized that this licensing strategy aligns with the company’s goal to collaborate with strong regional players, thereby maximizing patient outreach and shareholder returns.
Further details are expected within 60 days once the definitive agreement is finalized. Ocugen is currently in Phase 3 of clinical development for OCU400, with a target date for a Biologics License Application set for mid-2026.
About Ocugen, Inc.
Ocugen, Inc. is dedicated to the development of innovative gene therapies addressing major blindness diseases, aiming to transform patient lives through innovative scientific advancements. The company’s unique gene-agnostic approach positions it to meet significant unmet medical needs within large patient populations.
Cautionary Note
This announcement contains forward-looking statements regarding the licensing agreement and its potential benefits. Risks and uncertainties could impact the successful execution and outcomes of the agreement and ongoing clinical trials. For more information on these risks, refer to Ocugen’s filings with the Securities and Exchange Commission (SEC).
The content above is a summary. For more details, see the source article.